Rosiglitazone Adjunctive Therapy for Severe Malaria in Children

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
Even with optimal anti-malaria therapy and supportive care, severe and cerebral malaria are associated with a 10-30% mortality rate and neurocognitive deficits in up to 33% of survivors. Adjunctive therapies that modify host immune-pathological processes may further improve outcome over that possible with anti-malarials alone. Investigators aim to evaluate a PPARγ agonist ( \"rosiglitazone\") as adjunctive therapy for severe malaria.
Epistemonikos ID: c4a4658974c8f7150c4de98013591c7d46616861
First added on: May 12, 2024